109 related articles for article (PubMed ID: 30376198)
1. Mass spectrometric discrimination of phospholipid patterns in cisplatin-resistant and -sensitive cancer cells.
Cadoni E; Vanhara P; Valletta E; Pinna E; Vascellari S; Caddeo G; Isaia F; Pani A; Havel J; Pivetta T
Rapid Commun Mass Spectrom; 2019 Jan; 33(1):97-106. PubMed ID: 30376198
[TBL] [Abstract][Full Text] [Related]
2. Mixed copper-platinum complex formation could explain synergistic antiproliferative effect exhibited by binary mixtures of cisplatin and copper-1,10-phenanthroline compounds: An ESI-MS study.
Pivetta T; Lallai V; Valletta E; Trudu F; Isaia F; Perra D; Pinna E; Pani A
J Inorg Biochem; 2015 Oct; 151():107-14. PubMed ID: 26021964
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial proteomic analysis of cisplatin resistance in ovarian cancer.
Chappell NP; Teng PN; Hood BL; Wang G; Darcy KM; Hamilton CA; Maxwell GL; Conrads TP
J Proteome Res; 2012 Sep; 11(9):4605-14. PubMed ID: 22900918
[TBL] [Abstract][Full Text] [Related]
4. Reversed phase and cation exchange liquid chromatography with spectrophotometric and elemental/molecular mass spectrometric detection for S-adenosyl methionine/S-adenosyl homocysteine ratios as methylation index in cell cultures of ovarian cancer.
Iglesias González T; Cinti M; Montes-Bayón M; Fernández de la Campa MR; Blanco-González E
J Chromatogr A; 2015 May; 1393():89-95. PubMed ID: 25836049
[TBL] [Abstract][Full Text] [Related]
5. Quantitative evaluation of cellular uptake, DNA incorporation and adduct formation in cisplatin sensitive and resistant cell lines: Comparison of different Pt-containing drugs.
Corte-Rodríguez M; Espina M; Sierra LM; Blanco E; Ames T; Montes-Bayón M; Sanz-Medel A
Biochem Pharmacol; 2015 Nov; 98(1):69-77. PubMed ID: 26352094
[TBL] [Abstract][Full Text] [Related]
6. Proteomic analysis of cisplatin resistance in human ovarian cancer using 2-DE method.
Gong F; Peng X; Zeng Z; Yu M; Zhao Y; Tong A
Mol Cell Biochem; 2011 Feb; 348(1-2):141-7. PubMed ID: 21080034
[TBL] [Abstract][Full Text] [Related]
7. A shotgun tandem mass spectrometric analysis of phospholipids with normal-phase and/or reverse-phase liquid chromatography/electrospray ionization mass spectrometry.
Houjou T; Yamatani K; Imagawa M; Shimizu T; Taguchi R
Rapid Commun Mass Spectrom; 2005; 19(5):654-66. PubMed ID: 15700236
[TBL] [Abstract][Full Text] [Related]
8. Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model.
Zhao H; Wei W; Sun Y; Gao J; Wang Q; Zheng J
DNA Cell Biol; 2015 Jan; 34(1):55-62. PubMed ID: 25211326
[TBL] [Abstract][Full Text] [Related]
9. Immune modulator CD70 as a potential cisplatin resistance predictive marker in ovarian cancer.
Aggarwal S; He T; Fitzhugh W; Rosenthal K; Feild B; Heidbrink J; Mesmer D; Ruben SM; Moore PA
Gynecol Oncol; 2009 Dec; 115(3):430-7. PubMed ID: 19800108
[TBL] [Abstract][Full Text] [Related]
10. Differences in cisplatin distribution in sensitive and resistant ovarian cancer cells: a TEM/NanoSIMS study.
Lee RFS; Riedel T; Escrig S; Maclachlan C; Knott GW; Davey CA; Johnsson K; Meibom A; Dyson PJ
Metallomics; 2017 Oct; 9(10):1413-1420. PubMed ID: 28913538
[TBL] [Abstract][Full Text] [Related]
11. Regulation of HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells.
Yang X; Xing H; Gao Q; Chen G; Lu Y; Wang S; Ma D
Gynecol Oncol; 2005 May; 97(2):413-21. PubMed ID: 15863139
[TBL] [Abstract][Full Text] [Related]
12. NMR Metabolomics of Primary Ovarian Cancer Cells in Comparison to Established Cisplatin-Resistant and -Sensitive Cell Lines.
Ghini V; Sorbi F; Fambrini M; Magherini F
Cells; 2024 Apr; 13(8):. PubMed ID: 38667276
[TBL] [Abstract][Full Text] [Related]
13. The synthesis, chemical and biological properties of dichlorido(azpy)gold(III) chloride (azpy=2-(phenylazo)pyridine) and the gold-induced conversion of the azpy ligand to the chloride of the novel tricyclic pyrido[2,1-c][1,2,4]benzotriazin-11-ium cation.
Garza-Ortiz A; den Dulk H; Brouwer J; Kooijman H; Spek AL; Reedijk J
J Inorg Biochem; 2007 Nov; 101(11-12):1922-30. PubMed ID: 17637477
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
15. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
McEvoy LM; O'Toole SA; Spillane CD; Martin CM; Gallagher MF; Stordal B; Blackshields G; Sheils O; O'Leary JJ
BMC Cancer; 2015 Jul; 15():547. PubMed ID: 26205780
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of vimentin expression increased drug resistance in ovarian cancer cells.
Huo Y; Zheng Z; Chen Y; Wang Q; Zhang Z; Deng H
Oncotarget; 2016 Jul; 7(29):45876-45888. PubMed ID: 27322682
[TBL] [Abstract][Full Text] [Related]
17. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
18. [Regulatory effects and associated mechanisms of miR-130a molecules on cisplatin resistance in ovarian cancer A2780 cell lines].
Li NW; Wang HJ; Yang LY; Jia XB; Chen C; Wang X
Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 Nov; 44(6):865-70. PubMed ID: 24490491
[TBL] [Abstract][Full Text] [Related]
19. [Expression of miR-130a in cisplatin resistant cell lines of ovarian cancer].
Yang LY; Wang HJ; Jia XB; Wang X; Luo J; Zhang XY
Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Jan; 43(1):60-4. PubMed ID: 22455133
[TBL] [Abstract][Full Text] [Related]
20. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]